Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SABRIL safely and effectively. See full prescribing information for SABRIL . SABRIL ® ( vigabatrin ) t ablet s , for oral use SABRIL ® ( vigabatrin ) for o ral s olution Initial U.S. Approval: 2009
Medication labelWhy this: Advisory · dailymed-prescription
SABRIL is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions (5.1)]. SABRIL is not indicated as a first line agent for complex partial seizures. SABRIL is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions (5.1) ].
- generic_name
- vigabatrin
- product_names
- vigabatrin
- ndc
- 67386-211, 67386-211-65
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en